Teaming up: 2 Houston-based tech companies enter strategic partnerships for global opportunities

News briefs

Houston-based companies Alert Logic and Innowatts each announced partnerships that will provide international opportunities. Getty Images

Not sure if it's because of a rush to close 2018 deals before year end or just the collaborative holiday spirit, but two Houston-based, tech-focused companies have announced partnerships with other service companies that will expand the two entities' reach worldwide.

Innowatts Inc. inks partnership, expands into Japanese market

Courtesy of Innowatts

A Houston utilities analytics company has linked up with one of Japan's largest consulting and management advisory firms to bring its software and AI technology to the country's newly deregulated energy market. Innowatts announced the strategic regional partnership with ABeam Consulting December 13.

Innowatts launched in 2013 and has provided about 20 million retail energy consumers with cost-cutting predictive energy analytics. The new alliance will allow Innowatts to utilize its analysis software and AI-enabled technology in Japan's evolving energy market.

"As market reforms take hold and competitive pressures increase, it's important that we provide our clients the most effective tools and solutions to help them compete effectively," Takahiro Yamada, principal and head of financial and social infrastructure business unit of ABeam, says in the release. "Adding the Innowatts technology to our solution suite adds a wide range of new tools and capabilities that leverages the experience of some of the world's largest and most competitive retail energy markets."

Entering the Japanese market, Innowatts' focus will be on reaching out to new retail energy providers.

"As one of the largest and most respected consulting firms and system integrators in Japan, ABeam brings a deep body of energy industry expertise and regional knowledge that will help us localize and scale our eUtility™ Platform to Japan and other Asia Pacific energy markets," said Sid Sachdeva, CEO of Innowatts.

Innowatts employs 55 people — roughly half are based in Houston — and has clients in the United States, Canada, and Europe.

In October, Innowatts appointed Krishnan Kasiviswanathan as chief commercial officer, overseeing the upstream sector of development. He's based in the Houston office. Prior to the appointment, Kasiviswanathan worked as chief commercial officer at Just Energy, a Houston-based retail energy company.

Alert Logic taps Chicago-based AVANT as first master agent partner

Photo via alertlogic.com

Houston-based, security-as-a-service company, Alert Logic, has its first master agency partner. The collaboration means AVANT Communications, a technology distribution and channel enablement company, can sell Alert Logic's software and services. The partnership was announced on December 11.

Christopher Rajiah, senior vice president of global alliances and partnerships at Alert Logic, says in the release that its AVANT's global network and trusted advisers that made the partnership so appealing.

"AVANT is an exceptional partner to bring Alert Logic to the Agent Channel community. This partnership will power AVANT's network of Trusted Advisors to help businesses navigate today's ever-changing threat landscape, while addressing compliance risks and resource constraints," Rajiah says. "Together, we're going to bring SIEMless Threat Management to organizations worldwide."

Alert Logic announced its SIEMless Threat Management™ in November as its new all-encompassing security technology at an affordable price for lower resourced companies.

"The partnership with AVANT is the first of its kind for Alert Logic and will be directly enabled through the agent channel community at a very critical time, when the growing shortage of security talent is driving the highest demand ever for managed security offerings," says Ian Kieninger, CEO and co-founder of AVANT, in the release. "Welcoming Alert Logic to our expanding portfolio of security services will advance our mission to drive the agent community into one of the fastest-growing sectors of the information technology industry. This is going to drive sales for our network of Trusted Advisors now and in the months and years to come."

Chris Church and Misha Govshteyn founded Alert Logic in 2002. The two now lead electronics manufacturing company, MacroFab.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings